Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE DATED MAY 6, 2014 - UROLOGIX INC | urologix141724_ex99-1.htm |
|
|
|
|
|
UNITED STATES |
||
|
SECURITIES AND EXCHANGE COMMISSION |
||
|
Washington, D.C. 20549 |
||
|
|
|
|
|
|
|
|
|
FORM 8-K |
||
|
|
|
|
|
|
|
|
|
CURRENT REPORT |
||
|
|
||
|
PURSUANT TO SECTION 13 OR 15(d) OF |
||
|
THE SECURITIES EXCHANGE ACT OF 1934 |
||
|
|
|
|
|
Date of Report (date of earliest event reported): May 6, 2014 |
||
|
|
|
|
|
|
|
|
|
|
Urologix, Inc. |
|
|
(Exact name of Registrant as Specified in its Charter) |
||
|
|
|
|
|
|
Minnesota |
|
|
(State Or Other Jurisdiction Of Incorporation) |
||
|
|
|
|
|
|
|
|
|
000-28414 |
|
|
41-1697237 |
|
|
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
||
|
|
|
|
|
|
|
|
|
14405 21st Avenue North |
|
|
|
|
|
|
Minneapolis, MN |
|
|
55447 |
|
|
(Address Of Principal Executive Offices) |
|
(Zip Code) |
|
||
|
|
|
|
|
|
(763) 475-1400 |
|
|
Registrant’s Telephone Number, Including Area Code |
||
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
|
|
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
||
|
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
||
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
||
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Items under Sections 1 and 3 through 8 are not applicable and therefore omitted.
|
|
|
|
ITEM 2.02 |
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. |
Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on May 6, 2014 disclosing material non-public information regarding the Company’s results of operations for the third fiscal quarter of fiscal year 2014 ended March 31, 2014.
|
|
|
|
ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS. |
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release issued on May 6, 2014. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
|
|
|
|
|
UROLOGIX, INC. |
|
|
|
|
|
|
|
|
|
By: |
/s/ Brian J. Smrdel |
|
|
|
|
Brian J. Smrdel |
|
|
|
|
Chief Financial Officer |
|
|
|
|
|
|
|
Date: May 7, 2014 |
|
|
|